2008
A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD. A Role for the Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. American Journal Of Pathology 2008, 172: 583-591. PMID: 18245812, PMCID: PMC2258251, DOI: 10.2353/ajpath.2008.070569.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisAdvanced glycation end productsRAGE-null micePulmonary fibrosisGlycation end productsIPF pathogenesisMouse modelNovel therapeutic targetHealthy adult animalsIPF patientsWild-type controlsDismal prognosisSevere fibrosisIPF tissueEffective therapyFibrotic lungsTherapeutic targetHistological scoringFibrosisLoss of RAGECell surface receptorsAdult animalsMiceEnd productsSoluble isoform
2006
RAGE: A beneficial role in pulmonary fibrosis
Oury T, Hanford L, Kaminski N, Fattman C, Tan R, Tobloewski J, Kasper M, Bierhaus A. RAGE: A beneficial role in pulmonary fibrosis. The FASEB Journal 2006, 20: a213-a213. DOI: 10.1096/fasebj.20.4.a213.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisRAGE-null micePulmonary fibrosisMouse modelPulmonary fibroblastsPathogenesis of IPFNull miceAdvanced glycation end productsHuman IPF lungsSmooth muscle actin expressionRole of RAGEWild-type miceGlycation end productsNew therapeutic targetsMuscle actin expressionHuman fibrotic lungsHuman pulmonary fibroblastsPulmonary histologyIPF pathogenesisIPF lungsPulmonary diseasePoor prognosisIPF tissueRAGE expressionEffective therapy